All Comments by Hugo Geerts
Go to another page:
- 1
- 2
- Topline Result for First DIAN-TU Clinical Trial: Negative on Primary
- At CTAD, Early Failures and Hints of Success, from Small Trials
- ‘Reports of My Death Are Greatly Exaggerated.’ Signed, Aducanumab
- Scratch Lanabecestat: This BACE Inhibitor Doesn’t Work in Symptomatic AD, Either
- Boehringer Ingelheim Bails on Candidate Alzheimer’s Drug
- Merck Axes Verubecestat for Prodromal AD, Researchers Say ‘Go Earlier’
- RIP: Serotonin Receptor 5-HT6 Antagonist
- Merck Pulls Plug on Phase 2/3 BACE Inhibitor Trial
- Building Better Mouse Models for Late-Onset Alzheimer’s
- Massive Mouse Study Bolsters Rationale for Combination Therapy
- Advisory Panel Grapples with Combination Therapy
- Shape of a Hug: How the Embrace of a Therapeutic Aβ Antibody Really Matters
- Computational Modeling—Will it Rescue AD Clinical Trials?
- As DIAN Plans Trial Number Two, the Goal Is to Go Big
- TREM2 Mystery: Altered Microglia, No Effect on Plaques